PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	Adenoma, Oxyphilic, Head and Neck Neoplasms, Hurthle Cell Tumor, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, adenocarcinoma, adenoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, poorly differentiated thyroid gland carcinoma, thyroid Hurthle cell carcinoma, thyroid cancer, nonmedullary, 2, thyroid gland disorder, thyroid gland follicular carcinoma, thyroid tumor	Active, not recruiting	Phase 2	2026-09-17		NCT04544111

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Memorial Sloan Kettering Cancer Center	753

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge	United States	131
Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	United States	184
Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	United States	230
Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)	Commack	United States	7
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	United States	186
Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Rockville Centre	United States	35
Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison	United States	166